(Q40429629)

20 September 2017

Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs (English)

1 reference

20 September 2017

0 references

5

1 reference

20 September 2017

Kumar S

1

1 reference

20 September 2017

Raje N

2

1 reference

20 September 2017

Hideshima T

3

1 reference

20 September 2017

Ishitsuka K

4

1 reference

20 September 2017

Shiraishi N

6

1 reference

20 September 2017

Hamasaki M

7

1 reference

20 September 2017

Yasui H

8

1 reference

20 September 2017

Munshi NC

9

1 reference

20 September 2017

Richardson P

10

1 reference

20 September 2017

Figg WD

11

1 reference

20 September 2017

Anderson KC

12

1 reference

20 September 2017

1 July 2005

1 reference

20 September 2017

1 reference

20 September 2017

19

1 reference

20 September 2017

7

1 reference

20 September 2017

1253-1261

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403776

20 September 2017

0 references

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403776

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403776

1 reference

Dimensions Publication ID

20 September 2017

0 references

1 reference